Table 2.
Analysis to Assess the Factors Associated with Onset Interval of the Retinal Vessel Occlusion after SARS-CoV-2 Vaccination
| Retinal Vein Occlusion |
Retinal Artery Occlusion |
|||
|---|---|---|---|---|
| Mean Onset Interval (in Days) | P Value | Mean Onset Interval (in Days) | P Value | |
| Vaccine∗ | ||||
| BNT162b2 | 18.07 ± 28.66 | < 0.001 | 22.55 ± 40.00 | 0.723 |
| mRNA-1273 | 22.85 ± 38.13 | 28.40 ± 50.82 | ||
| Ad26.Cov2.s | 54.07 ± 88.98 | 27.17 ± 36.27 | ||
| Sex | ||||
| Female | 18.65 ± 28.73 | 0.1653 | 23.21 ± 42.57 | 0.7591 |
| Male | 22.46 ± 41.85 | 24.51 ± 41.69 | ||
| Age | ||||
| 0–10 | 0 | 0.0056 | 0 | 0.288 |
| 11–20 | 24.28 ± 37.94 | 27.33 ± 27.50 | ||
| 21–30 | 60.03 ± 90.01 | 20 ± 20.17 | ||
| 31–40 | 17.03 ± 23.69 | 38.61 ± 49.02 | ||
| 41–50 | 14.11 ± 16.18 | 30.15 ± 54.17 | ||
| 51–60 | 22.31 ± 38.06 | 30.69 ± 46.10 | ||
| 61–70 | 16.6 ± 27.15 | 19.43 ± 37.44 | ||
| 71–80 | 19.54 ± 30.77 | 15.47 ± 31.35 | ||
| 81–90 | 20.96 ± 34.94 | 29.31 ± 51.15 | ||
| 91–100 | 7.33 ± 6.02 | 50.2 ± 83.16 | ||
| Dosage | ||||
| 1 | 19.01 ± 36.64 | 0.249 | 17.55 ± 33.21 | 0.422 |
| 2 | 25.66 ± 40.93 | 29.82 ± 49.80 | ||
| 3 | 15.09 ± 23.65 | 29.78 ± 41.63 | ||
| 4 | 2 ± 3.46 | 3 ± 4.24 | ||
SARS-CoV-2 = severe acute respiratory syndrome coronavirus.
∗
One-way analysis of variance test and unpaired t test.